AIM ImmunoTech (AMEX:AIM) reported quarterly losses of $(0.10) per share. This is a 16.67 percent increase over losses of $(0.12) per share from the same period last year.
Cathie Wood Outlines Role Of Bitcoin Post ETF Approval, Praises 21Shares: ‘The Plumbing Works’
Signs that the U.S. Securities and Exchange Commission (SEC) will approve a Spot Bitcoin exchange-traded fund (ETF) in January are "very encouraging.